Improving treatment planning for recurrent colorectal cancer using MRI
Investigating the Origins of Pelvic Recurrence in Colorectal Cancer
This study is testing a new way to use MRI scans to help doctors plan better treatments for patients with recurrent colorectal cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 383 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Imperial College London Academic / other |
| Locations | 4 sites (Oslo and 3 other locations) |
| Trial ID | NCT02292641 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance surgical and treatment planning for patients with recurrent colorectal cancer by implementing a new radiological staging classification system. It involves both prospective and retrospective assessments of patients' original primary tumor scans and surgical specimens to identify risk factors for recurrence. Participants will undergo high-resolution MRI for staging, and their treatment outcomes will be monitored over a three-year follow-up period. The study seeks to improve understanding of disease recurrence and optimize treatment strategies.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 16 and over with a confirmed diagnosis of recurrent pelvic colorectal cancer who have previously undergone surgical treatment for primary adenocarcinoma.
Not a fit: Patients with irresectable extra-pelvic metastatic disease or those without available original staging scans will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatment planning and improved outcomes for patients with recurrent colorectal cancer.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques for cancer staging, suggesting that this approach may yield beneficial results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Had a primary colorectal adenocarcinoma proven by biopsy taken as part of routine clinical practice 2. Has a confirmed diagnosis of recurrent pelvic colorectal cancer 3. Has previously completed surgical treatment of primary adenocarcinoma of the colon, sigmoid colon or rectum 4. Are able to undergo high resolution MRI for staging prior to treatment decisions 5. Have provided written informed consent to participate in the study 6. Be aged 16 years or over Exclusion Criteria: 1. Have irresectable extra-pelvic metastatic disease 2. Original baseline staging and preoperative restaging scans (MR for rectal and sigmoid cancers and/or CT for colon and sigmoid cancers) are unavailable 3. Original preoperative, surgical and adjuvant treatment has not been documented or is unavailable
Where this trial is running
Oslo and 3 other locations
- Oslo University Hospital — Oslo, Norway (Recruiting)
- St Mark's Hospital — Harrow, London, United Kingdom (Recruiting)
- Churchill Hospital — Oxford, Oxfordshire, United Kingdom (Recruiting)
- Royal Marsden Hospital NHS Foundation Trust — Sutton, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Gina Dr Brown, MD — Imperial College London
- Study coordinator: Caroline Martin
- Email: c.martin1@imperial.ac.uk
- Phone: +44 (0) 7749 655 817
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.